The Role of mTOR Inhibitors in Breast Cancer

Jan 31, 2017 by in ONCOLOGY Comments Off on The Role of mTOR Inhibitors in Breast Cancer

  Patient population N Design Treatment arms Stratification factors Endpoints Results BOLERO-1 HER2+ ABC. First line 719 Randomization 2:1 Everolimus or placebo 10 mg/day + paclitaxel 80 mg/m2 days 1, 8, 15 + trastuzumab…

read more

Targeting mTOR: A Little Bit of History and a Large Future

Jan 31, 2017 by in ONCOLOGY Comments Off on Targeting mTOR: A Little Bit of History and a Large Future

Fig. 1.1 Chemical structure of rapamycin and rapalogs. Rapalogs have the indicated O-substitutions at the C-40 position of rapamycin (red circle) Temsirolimus, formerly known as CCI-779; Torcel®, Wyeth Pharmaceuticals, now…

read more
Get Clinical Tree app for offline access